Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France.

Bruley des Varannes S, Löfman HG, Karlsson M, Wahlqvist P, Ruth M, Furstnau ML, Despiégel N, Stålhammar NO.

BMC Gastroenterol. 2013 Feb 28;13:39. doi: 10.1186/1471-230X-13-39.

2.
3.

Systematic review: Patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease.

Hungin AP, Hill C, Molloy-Bland M, Raghunath A.

Clin Gastroenterol Hepatol. 2012 Feb;10(2):109-16. doi: 10.1016/j.cgh.2011.07.008. Review.

PMID:
21782770
4.

Economic evaluations of gastroesophageal reflux disease medical management.

Gawron AJ, French DD, Pandolfino JE, Howden CW.

Pharmacoeconomics. 2014 Aug;32(8):745-58. doi: 10.1007/s40273-014-0164-8. Review.

5.

Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis.

Ren LH, Chen WX, Qian LJ, Li S, Gu M, Shi RH.

World J Gastroenterol. 2014 Mar 7;20(9):2412-9. doi: 10.3748/wjg.v20.i9.2412. Review.

6.

The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease.

Ofman JJ.

Am J Gastroenterol. 2003 Mar;98(3 Suppl):S8-S14. Review.

PMID:
12644026
7.

Refractory GERD: what is it?

Fass R, Gasiorowska A.

Curr Gastroenterol Rep. 2008 Jun;10(3):252-7. Review.

PMID:
18625135
8.

GERD: An Alternative Perspective.

Ho CE, Goh YL, Zhao XX, Yu CY, Zhang C.

Psychosomatics. 2016 Mar-Apr;57(2):142-51. doi: 10.1016/j.psym.2015.10.007. Review.

PMID:
26895729
Items per page

Supplemental Content

Support Center